Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haojun Chen

Showing results (141-150 of 148) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 148 results.
European Journal of Nuclear Medicine and Molecular Imaging|May 1, 2025
Fibroblast activation protein-targeted PET/CT with <sup>68</sup>Ga-FAPI-46 for evaluation of structural damage and inflammation in axial spondyloarthritis: a prospective studyYangchun Chen, Lingyu Yu, Shiju Chen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 31, 2020
Comparison of [<sup>68</sup>Ga]Ga-DOTA-FAPI-04 and [<sup>18</sup>F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancerHaojun Chen, Yizhen Pang, Jingxun Wu, et al.
The Journal of Clinical Investigation|November 7, 2024
68Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancerHaojun Chen, Liang Zhao, Yizhen Pang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2025
177Lu-LNC1004 Radioligand Therapy in Patients with End-stage Metastatic Cancers: A Single-Center, Single-Arm, Phase II StudyHao Fu, Jingxiong Huang, Liang Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2022
A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor EffectXuejun Wen, Changrong Shi, Xinying Zeng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2025
68Ga-NK224 PET/CT for Non-Invasive Evaluation of PD-L1 Expression and Inter-Tumor Heterogeneity: A Translational Exploratory StudyLiang Zhao, Yizhen Pang, Yi Ding, et al.
Signal Transduction and Targeted Therapy|June 2, 2024
Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockadeLiang Zhao, Yizhen Pang, Yangfan Zhou, et al.
Acta Pharmaceutica Sinica. B|April 3, 2025
Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human studyWei Guo, Xuejun Wen, Yuhang Chen, et al.
Pageof 15

Showing results (141-150 of 148) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 148 results.
European Journal of Nuclear Medicine and Molecular Imaging|May 1, 2025
Fibroblast activation protein-targeted PET/CT with <sup>68</sup>Ga-FAPI-46 for evaluation of structural damage and inflammation in axial spondyloarthritis: a prospective studyYangchun Chen, Lingyu Yu, Shiju Chen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 31, 2020
Comparison of [<sup>68</sup>Ga]Ga-DOTA-FAPI-04 and [<sup>18</sup>F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancerHaojun Chen, Yizhen Pang, Jingxun Wu, et al.
The Journal of Clinical Investigation|November 7, 2024
68Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancerHaojun Chen, Liang Zhao, Yizhen Pang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2025
177Lu-LNC1004 Radioligand Therapy in Patients with End-stage Metastatic Cancers: A Single-Center, Single-Arm, Phase II StudyHao Fu, Jingxiong Huang, Liang Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2022
A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor EffectXuejun Wen, Changrong Shi, Xinying Zeng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2025
68Ga-NK224 PET/CT for Non-Invasive Evaluation of PD-L1 Expression and Inter-Tumor Heterogeneity: A Translational Exploratory StudyLiang Zhao, Yizhen Pang, Yi Ding, et al.
Signal Transduction and Targeted Therapy|June 2, 2024
Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockadeLiang Zhao, Yizhen Pang, Yangfan Zhou, et al.
Acta Pharmaceutica Sinica. B|April 3, 2025
Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human studyWei Guo, Xuejun Wen, Yuhang Chen, et al.
Pageof 15